We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.
- Authors
Oliveira Monteiro, Maria Patrícia A; Salheb Oliveira, Danielle S M; Manzine, Patrícia R; Crispim Nascimento, Carla M; Dos Santos Orlandi, Ariene A; de Oliveira Gomes, Grace A; Dos Santos Orlandi, Fabiana; Zazzetta, Marisa S; Pott-Junior, Henrique; Cominetti, Marcia R
- Abstract
Blood-based biomarkers for Alzheimer's disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphorylated tau in cerebrospinal fluid (CSF); however, they are not attractive for large-scale screening. Blood-based biomarkers allow an initial large-scale screening of patients under suspicion that could later be tested for the already established CSF biomarkers. To this regard, in this study, we evaluated whether plasma ADAM10 levels would be predictors of declines in cognition in community-dwelling older adults after a 3-year period follow-up.
- Publication
Alzheimer's research & therapy, 2021, Vol 13, Issue 1, p18
- ISSN
1758-9193
- Publication type
Journal Article
- DOI
10.1186/s13195-020-00750-y